PM 1043
Alternative Names: PM-1043Latest Information Update: 24 May 2022
At a glance
- Originator Biotheus
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Apr 2022 PM 1043 is available for licensing as of 12 Apr 2022. https://cn.biotheus.com/Business_Partnership.html
- 05 Apr 2022 Preclinical trials in Cancer in China (unspecified route) (Biotheus website, April 2022)